Susquehanna International Group
VERV

Susquehanna International Group’s Verve Therapeutics VERV Stock Holding History

Susquehanna International Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-82,365
Closed -$925K – 13992
2025
Q2 		$925K Sell
82,365
-30,351
-27% -$173K ﹤0.01% 7632
2025
Q1 		$515K Buy
112,716
+70,232
+165% +$470K ﹤0.01% 8839
2024
Q4 		$240K Sell
42,484
-31,264
-42% -$176K ﹤0.01% 10305
2024
Q3 		$357K Sell
73,748
-118,658
-62% -$689K ﹤0.01% 9233
2024
Q2 		$939K Buy
192,406
+139,882
+266% +$879K ﹤0.01% 6733
2024
Q1 		$698K Sell
52,524
-76,192
-59% -$1.01M ﹤0.01% 7706
2023
Q4 		$1.79M Buy
128,716
+95,589
+289% +$1.18M ﹤0.01% 5598
2023
Q3 		$439K Buy
33,127
+12,264
+59% +$197K ﹤0.01% 8534
2023
Q2 		$391K Sell
20,863
-97,575
-82% -$1.63M ﹤0.01% 8886
2023
Q1 		$1.71M Buy
118,438
+45,019
+61% +$882K ﹤0.01% 5490
2022
Q4 		$1.42M Sell
73,419
-23,993
-25% -$636K ﹤0.01% 5405
2022
Q3 		$3.35M Buy
97,412
+76,802
+373% +$2.45M ﹤0.01% 3854
2022
Q2 		$315K Sell
20,610
-26,247
-56% -$407K ﹤0.01% 9449
2022
Q1 		$1.07M Sell
46,857
-10,405
-18% -$297K ﹤0.01% 6947
2021
Q4 		$2.11M Buy
+57,262
New +$2.41M ﹤0.01% 5377
2021
Q3 		– Sell
-28,525
Closed -$1.72M – 13641
2021
Q2 		$1.72M Buy
+28,525
New +$1.18M ﹤0.01% 6278

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Susquehanna International Group's VERV Position: Q3 2025 in Review

Susquehanna International Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 82,365 shares — an estimated $925K sold.

Susquehanna International Group first reported a position in VERV in Q2 2021 and held it in 16 quarters. The position peaked at $3.35M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Susquehanna International Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 82,365 Verve Therapeutics shares in Q3 2025, an estimated $925K.
  • Susquehanna International Group first reported a position in Verve Therapeutics in Q2 2021 and held it in 16 quarters.
  • Susquehanna International Group's Verve Therapeutics position peaked at $3.35M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.